← Eichor
Study identifier: NCT06056921 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Condition: SLE (Systemic Lupus) · Sjogren's Syndrome · Systemic Scleroderma  ·  Sponsor: Chongqing Precision Biotech Co., Ltd

PhasePhase 1
Planned participants24
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a single arm study to evaluate the efficacy and safety of CD19 targeted CAR-T cells therapy for patients with Refractory Autoimmune Disease

This description comes directly from the study's public registry record.

Talk to the study team

Liyun Zhang, M.D  ·  13834547708  ·  1315710223@qq.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanxi Bethune HospitalTaiyuan, Shanxi, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06056921